Premium
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Author(s) -
Goradel Nasser Hashemi,
Mohajel Nasir,
Malekshahi Ziba Veisi,
Jahangiri Samira,
Najafi Masoud,
Farhood Bagher,
Mortezaee Keywan,
Negahdari Babak,
Arashkia Arash
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27850
Subject(s) - oncolytic virus , oncolytic adenovirus , cancer , genome , cancer research , biology , immunotherapy , immune system , virotherapy , cancer cell , adenoviridae , genetic enhancement , virology , computational biology , immunology , tumor cells , gene , genetics
Abstract Cancer therapy using oncolytic viruses is an emerging area, in which viruses are engineered to selectively propagate in tumor tissues without affecting healthy cells. Because of the advantages that adenoviruses (Ads) have over other viruses, they are more considered. To achieve tumor selectivity, two main modifications on Ads genome have been applied: small deletions and insertion of tissue‐ or tumor‐specific promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune responses stimulation, to further increase their antitumor effects, genomic modifications have been carried out including insertion of checkpoint inhibitors and antigenic or immunostimulatory molecules into the adenovirus genome and combination with dendritic cells and chemotherapeutic agents. This study reviews oncolytic adenoviruses structures, their antitumor efficacy in combination with other therapeutic strategies, and finally challenges around this treatment approach.